Sherlock Biosciences: Revolutionizing Diagnostics with CRISPR and Engineering Bio

article image

Scientists behind some of the innovations that made CRISPR and other engineering biology technologies so powerful for drug R&D have founded a diagnostics company. They’re starting with rapid COVID-19 testing.

CRISPR, the extraordinary gene editing tool that is making drug development more effective, is revolutionizing scientific research from top to bottom. Now, years after it has infiltrated the therapeutic world, top-flight scientists behind some of the most important CRISPR breakthroughs are looking at its applications in diagnostics, including SARS-CoV-2 testing.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: